Norovirus vaccine recombinant monovalent - Takeda

Drug Profile

Norovirus vaccine recombinant monovalent - Takeda

Alternative Names: Norovirus dry powder vaccine - Takeda; Norovirus monovalent VLP vaccine - Takeda; Norwalk virus-like particle vaccine - Takeda

Latest Information Update: 21 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LigoCyte Pharmaceuticals
  • Developer Baylor College of Medicine; Takeda
  • Class Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Norovirus infections

Most Recent Events

  • 05 Aug 2014 Archimedes Pharma has been acquired by ProStrakan
  • 05 Oct 2012 LigoCyte Pharmaceuticals has been acquired and merged into Takeda
  • 25 Oct 2010 Efficacy & adverse events data from the phase I/II LV01-103 trial in Norovirus infections presented at the (48th Annual Meeting of the Infectious Diseases Society of America (IDSA-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top